POST Online Media Lite Edition


Carl Icahn takes 'large position' in Allergan

Staff writer |
Carl Icahn revealed a "large position" in Allergan, almost two months after the U.S. government blocked its $160 billion merger with Pfizer.

Article continues below

"We were instrumental in bringing Brent on board as the new CEO of Forest Labs a few years ago and worked cooperatively and constructively with him to help increase value for all Forest shareholders," the activist investor said.

"Less than a year later Forest was acquired by Actavis (which subsequently merged with Allergan) resulting in massive gains for Forest shareholders. While we at that time disposed of our position in Forest, we still have always maintained great respect for Brent."

What to read next

Carl Icahn sues Dell over shareholder meeting date
Icahn denies attempt to sell Herbalife stock
Carl Icahn and eBay settle proxy fight